Trial · NCT02031679
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Change in Diary-based Clinical Symptoms as Measured by the Urticaria Activity Score 7 (UAS7) | AZD1981 | Baseline | 20.46 | Standard Error 3.655 | UAS7 Scores |
| The Change in Diary-based Clinical Symptoms as Measured by the Urticaria Activity Score 7 (UAS7) | Placebo | Baseline | 24.59 | Standard Error 3.463 | UAS7 Scores |
| The Change in Diary-based Clinical Symptoms as Measured by the Urticaria Activity Score 7 (UAS7) | AZD1981 | End of Treatment | 18.83 | Standard Error 3.779 | UAS7 Scores |
| The Change in Diary-based Clinical Symptoms as Measured by the Urticaria Activity Score 7 (UAS7) | Placebo | End of Treatment | 18 | Standard Error 3.614 | UAS7 Scores |
| The Change in Diary-based Clinical Symptoms as Measured by the Urticaria Activity Score 7 (UAS7) | AZD1981 | End of Washout | 15.79 | Standard Error 3.726 | UAS7 Scores |
| The Change in Diary-based Clinical Symptoms as Measured by the Urticaria Activity Score 7 (UAS7) | Placebo | End of Washout | 19 | Standard Error 3.465 | UAS7 Scores |
| The Number of Participants With Adverse Events | AZD1981 | 9 | participants with adverse events | ||
| The Number of Participants With Adverse Events | Placebo | 8 | participants with adverse events | ||
| The Ability of AZD1981 to Inhibit Prostaglandin D2 (PGD2)-Induced Eosinophil Shape | AZD1981 | Baseline | 1521.317 | Standard Deviation 138.146 | Mean fluorescence units area under curve |
| The Ability of AZD1981 to Inhibit Prostaglandin D2 (PGD2)-Induced Eosinophil Shape | Placebo | Baseline | 1472.867 | Standard Deviation 184.401 | Mean fluorescence units area under curve |
| The Ability of AZD1981 to Inhibit Prostaglandin D2 (PGD2)-Induced Eosinophil Shape | AZD1981 | End of Treatment | 1435.540 | Standard Deviation 137.752 | Mean fluorescence units area under curve |
| The Ability of AZD1981 to Inhibit Prostaglandin D2 (PGD2)-Induced Eosinophil Shape | Placebo | End of Treatment | 1456.602 | Standard Deviation 157.485 | Mean fluorescence units area under curve |
| The Ability of AZD1981 to Inhibit Prostaglandin D2 (PGD2)-Induced Eosinophil Shape | AZD1981 | End of Washout | 1508.367 | Standard Deviation 116.085 | Mean fluorescence units area under curve |
| The Ability of AZD1981 to Inhibit Prostaglandin D2 (PGD2)-Induced Eosinophil Shape | Placebo | End of Washout | 1406.221 | Standard Deviation 108.539 | Mean fluorescence units area under curve |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02031679/results